REDWOOD CITY, Calif., May 15, 2020 (GLOBE NEWSWIRE) — Guardant Health, Inc. (Nasdaq: GH) along with leading academic institutions and pharmaceutical companies will present data highlighting the use of the company’s proprietary blood tests to advance precision oncology across the continuum of care at the upcoming 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, being held from May 29-31; and the AACR Virtual Annual Meeting II, scheduled for June 22-24.
More than 25 abstracts, now online, demonstrate how blood-based comprehensive genotyping is integral to the adoption of precision oncology in advanced cancer. The data highlights the use of Guardant360 and GuardantOMNI liquid biopsy tests to detect clinically actionable mutations and to help inform treatment for patients as their cancer progresses. Key findings demonstrate high concordance with tissue biopsies, the advantages over tissue biopsies to detect clinically relevant mutations for rule-in and rule-out decisions, and feasibility of serial testing from patient plasma to reveal tumor evolution and resistance in response to intervening therapies, including immunotherapies. Additionally, researchers will present data indicating the effectiveness of new targeted therapies.“Now more than ever, liquid biopsies can help overcome the barriers of tissue biopsies that this pandemic has either exacerbated or created for the most vulnerable of patients. The data presented at ASCO and AACR will further demonstrate the advantages of blood-based comprehensive genotyping to reveal critical genomic information that will improve the management of advanced cancer,” said Helmy Eltoukhy, Guardant Health co-founder and CEO. “We also look forward to sharing LUNAR-2 data demonstrating improved performance of our liquid biopsy in detecting early-stage colorectal cancer, and the progress of LUNAR-1 trials currently underway.”LUNAR-2 Liquid Biopsy Demonstrates Improved Performance in Detecting Early-Stage Colorectal CancerAACR data shows improved performance of the LUNAR-2 liquid biopsy to detect early-stage colorectal cancer (CRC) in average-risk adults. In a blinded cohort analysis of colonoscopy screened negative patients (n=88) and patients newly diagnosed with early stage CRC (n=113) using a further optimized, integrated genomic and epigenomic analysis, the LUNAR-2 assay demonstrated overall sensitivity of 90.3% and overall specificity of 96.6%, representing a slight improvement over previously reported data.Guardant360 Clinical-Genomic Dataset Highlights Value of Liquid Biopsy for Precision Oncology Drug DevelopmentAACR data quantifies the value of Guardant Health’s clinical-genomic real-world evidence (RWE) dataset, GuardantINFORM, to enable drug development using circulating tumor DNA (ctDNA) as an alternative to serial tissue testing. In a cohort of patients who underwent Guardant360 serial ctDNA testing (n=85,874) and linked to de-identified medical and pharmacy claims, a robust longitudinal view of the patients’ diagnosis, treatments, and clinical outcomes was accessible for a majority of patients. The availability of clinical-genomic information following systemic therapy confirms that this dataset could serve as a viable resource for precision oncology drug development researchers to evaluate drug resistance and tumor evolution in a real-world setting.Trials Underway Validating LUNAR-1 Liquid Biopsy to Inform Adjuvant Treatment for Colon CancerASCO data highlights the status of two prospective, multi-center clinical trials validating the clinical utility of the LUNAR-1 liquid biopsy to guide adjuvant treatment decisions for colon cancer.NRG-G1005 COBRA Study/Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Stage II Colon Cancer (NCT04068103)PEGASUS Trial/Post-Surgical Liquid Biopsy-Guided Treatment of Stage III and High-Risk Stage II Colon Cancer Patients (NCT04259944)Presentations at ASCO and AACRASCO 2020 Annual MeetingAACR Virtual Meeting IIAbout Guardant HealthGuardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has launched liquid biopsy-based Guardant360 and GuardantOMNI tests for advanced stage cancer patients. These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.Forward-looking StatementsThis press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential benefits and advantages of Guardant Health’s liquid biopsy tests or assays as well as its clinical-genomic dataset, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. Such risks and uncertainties include those discussed under the caption “Risk Factors” in Guardant Health’s Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the period ended March 31, 2020, and in its other reports filed with the Securities and Exchange Commission. These forward-looking statements are based on current expectations, forecasts, assumptions and information available to Guardant Health as of the date hereof, and actual outcomes and results could differ materially from these statements due to a number of factors, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release. Investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Guardant Health.Investor Contact:
Carrie Mendivil
investors@guardanthealth.comMedia Contact:
Anna Czene
press@guardanthealth.com
Bay Street News